haloperidol has been researched along with gsk 2334470 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kabir, M; Kerns, E; Nguyen, K; Shah, P; Sun, H; Wang, Y; Xu, X; Yu, KR | 1 |
| Itkin, M; Kabir, M; Mathé, EA; Nguyễn, ÐT; Padilha, EC; Shah, P; Shinn, P; Siramshetty, V; Wang, AQ; Williams, J; Xu, X; Yu, KR; Zhao, T | 1 |
1 review(s) available for haloperidol and gsk 2334470
| Article | Year |
|---|---|
Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability.
Topics: Administration, Oral; Animals; Betamethasone; Biological Availability; Caco-2 Cells; Cell Membrane Permeability; Cells, Cultured; Dexamethasone; Dogs; Dose-Response Relationship, Drug; Humans; Hydrogen-Ion Concentration; Madin Darby Canine Kidney Cells; Mice; Molecular Structure; Neural Networks, Computer; Ranitidine; Rats; Structure-Activity Relationship; Verapamil | 2022 |
1 other study(ies) available for haloperidol and gsk 2334470
| Article | Year |
|---|---|
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
Topics: Drug Discovery; Organic Chemicals; Pharmaceutical Preparations; Solubility | 2019 |